CTLA4 and melanoma: Kaplan–Meier survival analysis showed that IEVscore stratified melanoma patients (Vanallen cohort) into two groups with different prognoses, with patients having high-IEVscores showing poorer clinical outcomes (Fig. 7D) and greater resistance to anti-CTLA4 therapy (Fig. 7E).